5 recruiting. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 5 |
| Phase 1 | 3 | Recruiting 3 |
Follow Rescue Medications: new trials by email Literature Review of Rescue Medications trials Research Report on Rescue Medications
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) MK-1084, Patritumab deruxtecan, Sacituzumab tirumotecan - Lung Neoplasm Malignant | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 140 | 2026-04-30 | 2026-10-01 |
| A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) Gocatamig, I-DXd, Atezolizumab - Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 170 | 2026-01-29 | 2026-10-20 |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate - Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 250 | 2025-08-11 | 2026-10-06 |
| Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) R-DXD, I-DXD, Docetaxel - Lung Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 144 | 2025-05-28 | 2026-10-07 |
| Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan - Gastroesophageal Junction, Gastroesophageal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 210 | 2024-08-07 | 2026-09-03 |
Lung Neoplasms (2) · Esophageal Neoplasms (1) · Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
Chile (5) · United States (5) · China (4) · Germany (4) · Italy (4) · Spain (4) · Brazil (3) · Greece (3) · Israel (3) · South Korea (3) · Turkey (Türkiye) (3) · Argentina (2) · Poland (2) · Taiwan (2) · Thailand (2)
2023 (1), 2025 (1)